PureTech Health (NASDAQ:PRTC) Shares Down 6.7% – What’s Next?

PureTech Health plc (NASDAQ:PRTC)’s stock price traded down 6.7% on Monday . The stock traded as low as $21.29 and last traded at $21.29. 943 shares traded hands during trading, a decline of 77% from the average session volume of 4,061 shares. The stock had previously closed at $22.82.

Analysts Set New Price Targets

A number of equities analysts have issued reports on PRTC shares. Leerink Partners started coverage on PureTech Health in a report on Monday, September 9th. They set an “outperform” rating and a $45.00 target price on the stock. Leerink Partnrs raised PureTech Health to a “strong-buy” rating in a report on Monday, September 9th.

PureTech Health Trading Down 4.3 %

The firm has a fifty day simple moving average of $20.41 and a 200-day simple moving average of $23.48.

Institutional Trading of PureTech Health

A hedge fund recently bought a new stake in PureTech Health stock. Birch Hill Investment Advisors LLC purchased a new stake in PureTech Health plc (NASDAQ:PRTC) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 302,000 shares of the company’s stock, valued at approximately $7,550,000. Birch Hill Investment Advisors LLC owned 1.26% of PureTech Health at the end of the most recent reporting period. Institutional investors and hedge funds own 0.04% of the company’s stock.

About PureTech Health

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.